Matching-Adjusted Indirect Comparison of Axicabtagene Ciloleucel vs Odronextamab for the Treatment of Relapsed/Refractory (R/R) Large B- Cell Lymphoma (LBCL) After 2 Prior Lines of Systemic Treatment

被引：0

作者：

Locke, Frederick L. ^{[1
]}

Popoff, Evan ^{[2
]}

Wade, Sally W. ^{[3
]}

Limbrick-Oldfield, Eve ^{[2
]}

Kanters, Steve ^{[2
]}

Palivela, Madhu ^{[4
]}

Best, Timothy ^{[4
]}

Ray, Markqayne ^{[4
]}

Oluwole, Olalekan O. ^{[5
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa Bay, FL USA

[2] RainCity Analyt, Vancouver, BC, Canada

[3] Wade Outcomes Res & Consulting, Salt Lake City, UT USA

[4] Kite, Santa Monica, CA USA

[5] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

来源：

关键词：

ABCL; axi-cel; odronextamab; LBCL; relapsed/refractory; MAIC;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-411

引用

页码：S478 / S478

页数：1